Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease PharmaTimesSubcutaneous delivery shows IVlevel efficacy in moderate to severe TEDClinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED Clinical DataOphthalmologyRead full story Post navigation Previous: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing ChangesNext: Kennedy changes vaccine panel charter after legal setback Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
